



PATIENTS PREVIOUSLY USING BUSCOPAN MAY NOT BE AWARE THE PRODUCT IS AVAILABLE AT YOUR PHARMACY.

Patients have indicated high satisfaction with Buscopan² and is advantageous that they are aware that it is back in stock.

Free Accredited Online CHE

To learn more about Antispasmodics for the Management & Self Treatment of abdominal pain and cramping, visit:



www.mdbriefcase.com/antispasmodics-mainpro/



DUAL BENEFIT BUSCOPAN® RELAXES TIGHT MUSCLES TO RELIEVE ABDOMINAL CRAMPS AND PAIN³

PROVEN SAFETY PROFILE

The anticholinergic side effects of **Buscopan**[®] are generally mild and self-limited.

TARGETED RELIEF

For abdominal pain and discomfort. Works at the site of pain, where the cramps occur – in the GI system.


WELL-TOLERATED

<1% absorbed into the bloodstream (low bioavailability).

NOW LACTOSE FREE

Buscopan® is available in tablet form:*

Tablets, 10 mg hyoscine butylbromide



• Following oral administration of **Buscopan**®, the systemic availability was found to be less than 1%**.1

* **Buscopan**[®] should not be taken on a continuous daily basis or for extended periods without investigating the cause of abdominal pain. ** clinical significance has not been established.



COMPOSITION¹

Medicinal ingredient: hyoscine butylbromide. Non-medicinal ingredients: acacia, anhydrous dibasic calcium phosphate, carnauba wax, colloidal silicon dioxide, corn starch, modified starch, polyethylene glycol 6000, povidone, stearic acid, sucrose, talc, tartaric acid, titanium dioxide, and white wax.

For more information:

Please consult the Product Monograph at http://products.sanofi.ca/en/buscopan.pdf or contact the sponsor, Sanofi-Aventis Canada Inc., at 1-800-265-7927 for important information to assist in benefit-risk assessment. Always direct the patient to read and follow the label.

> **REFERENCES** 1. Sanofi-Aventis Canada Inc. Buscopan® Product Monograph. September 6, 2018. 2. Sanofi-Aventis Canada Inc. Buscopan® Data on File. 2017.



SACA.BUSC.19.03.0206b